


## Rilpivirine

Cat. No.:	HY-10574
CAS No.:	500287-72-9
Molecular Formula:	C <sub>22</sub> H <sub>18</sub> N <sub>6</sub>
Molecular Weight:	366.42
Target:	HIV; Reverse Transcriptase
Pathway:	Anti-infection
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    1 year -20°C    6 months



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (136.46 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.7291 mL	13.6455 mL	27.2911 mL
		5 mM		0.5458 mL	2.7291 mL	5.4582 mL
		10 mM		0.2729 mL	1.3646 mL	2.7291 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3 mg/mL (8.19 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 3 mg/mL (8.19 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3 mg/mL (8.19 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC <sub>50</sub> =0.4 nM) and mutant viruses (EC <sub>50</sub> =0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	reverse transcriptase <sup>[1]</sup> HIV <sup>[1]</sup>

<b>In Vitro</b>	<p>R278474 is active against wild-type HIV-1 (<math>EC_{50}=0.4</math> nM) and all single and double mutants tested (<math>EC_{50}=0.1-2.0</math> nM)<sup>[1]</sup>. R278474 (10-5000 nM; 30 d) does not observe the sign of wild-type HIV-1 breakthrough at 1 <math>\mu</math>M within 30 days<sup>[1]</sup>. R278474 inhibits 81% of clinical isolates (about 1200 recombinant clinical isolates) at a 50% inhibitory concentration (<math>EC_{50}</math>) less than 1 nM, and inhibits 94% at <math>EC_{50}</math> less than 10 nM<sup>[1]</sup>. TMC278 shows subnanomolar <math>EC_{50}</math>s against wild-type HIV-1 group M isolates (0.07-1.01 nM) and nanomolar <math>EC_{50}</math>s against group O isolates (2.88-8.45 nM) in MT4 T-cells<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>R278474 (10-160 mg/kg; p.o. for 1 month) does not produce abnormal effects in rat, apart from liver weight increase and species-specific thyroid hypertrophy, both at the higher dose levels<sup>[1]</sup>. R278474 (i.v.) exhibits elimination half-life ranges from 4.4 h in rat to 31 h in dog, and exposure (<math>AUC_{inf}</math>) amounts to 3.1 <math>\mu</math>g·h/mL (4 mg/kg) in rat, 8.7 <math>\mu</math>g·h/mL (1.25 mg/kg) in dog, 1.4 <math>\mu</math>g·h/mL (1.25 mg/kg) in monkey, and 44·<math>\mu</math>g h/mL (1.25 mg/kg) in rabbit<sup>[1]</sup>. R278474 (p.o.) exhibits half-life ranges between 2.8 h in rat and 39 h in dog, and oral bioavailability of 32% and 31% in rat and dog<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## CUSTOMER VALIDATION

- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- Br J Cancer. 2023 Jan 30.
- Pharmaceuticals. 2022, 15(10), 1186.
- Sci Rep. 2015 Oct 29;5:15806.
- PLoS One. 2021 Mar 10;16(3):e0248139.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Janssen PAJ, et, al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem. 2005 Mar 24;48(6):1
- [2]. Azijn H, et, al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010 Feb;54(2):718-27.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



Revision Date: Jan.-29-2022  
Print Date: Sep.-21-2023

## 1. PRODUCT AND COMPANY IDENTIFICATION

### 1.1 Product identifier

Product name : Rilpivirine  
Catalog No. : HY-10574  
CAS No. : 500287-72-9

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, manufacture of substances.

### 1.3 Details of the supplier of the safety data sheet

Company: MedChemExpress USA  
Tel: 609-228-6898  
Fax: 609-228-5909  
E-mail: sales@medchemexpress.com

### 1.4 Emergency telephone number

Emergency Phone #: 609-228-6898

## 2. HAZARDS IDENTIFICATION

### 2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity, oral (Category 4), H302

### 2.2 GHS Label elements, including precautionary statements

Pictogram



Signal word Warning

Hazard statement(s)

H302 Harmful if swallowed

Precautionary statement(s)

Prevention

P280 Wear protective gloves/protective clothing/eye protection/face protection.

Response

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do.

Continue rinsing.

### 2.3 Other hazards

None.

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.1 Substances

Synonyms:	R278474; TMC278; DB08864
Formula:	$C_{22}H_{18}N_6$
Molecular Weight:	366.42
CAS No. :	500287-72-9

### 4. FIRST AID MEASURES

#### 4.1 Description of first aid measures

##### Eye contact

Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.

##### Skin contact

Rinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.

##### Inhalation

Immediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.

##### Ingestion

Wash out mouth with water; Do NOT induce vomiting; call a physician.

#### 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2).

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

### 5. FIRE FIGHTING MEASURES

#### 5.1 Extinguishing media

##### Suitable extinguishing media

Use water spray, dry chemical, foam, and carbon dioxide fire extinguisher.

#### 5.2 Special hazards arising from the substance or mixture

During combustion, may emit irritant fumes.

#### 5.3 Advice for firefighters

Wear self-contained breathing apparatus and protective clothing.

### 6. ACCIDENTAL RELEASE MEASURES

#### 6.1 Personal precautions, protective equipment and emergency procedures

Use full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.

Refer to protective measures listed in sections 8.

#### 6.2 Environmental precautions

Try to prevent further leakage or spillage. Keep the product away from drains or water courses.

#### 6.3 Methods and materials for containment and cleaning up

---

Absorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.

## 7. HANDLING AND STORAGE

### 7.1 Precautions for safe handling

Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.

### 7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.

Recommended storage temperature:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 years
		-20°C	6 months

Shipping at room temperature if less than 2 weeks.

### 7.3 Specific end use(s)

No data available.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1 Control parameters

#### Components with workplace control parameters

This product contains no substances with occupational exposure limit values.

### 8.2 Exposure controls

#### Engineering controls

Ensure adequate ventilation. Provide accessible safety shower and eye wash station.

#### Personal protective equipment

Eye protection	Safety goggles with side-shields.
Hand protection	Protective gloves.
Skin and body protection	Impervious clothing.
Respiratory protection	Suitable respirator.
Environmental exposure controls	Keep the product away from drains, water courses or the soil. Clean spillages in a safe way as soon as possible.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

### 9.1 Information on basic physical and chemical properties

Appearance	Solid
Odor	No data available
Odor threshold	No data available
pH	No data available
Melting/freezing point	245°C
Boiling point/range	634.1°C at 760 mmHg
Flash point	337.3°C

---

Evaporation rate	No data available
Flammability (solid, gas)	No data available
Upper/lower flammability or explosive limits	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water Solubility	No data available
Partition coefficient	No data available
Auto-ignition temperature	No data available
Decomposition temperature	No data available
Viscosity	No data available
Explosive properties	No data available
Oxidizing properties	No data available

## 9.2 Other safety information

No data available.

## 10. STABILITY AND REACTIVITY

### 10.1 Reactivity

No data available.

### 10.2 Chemical stability

Stable under recommended storage conditions.

### 10.3 Possibility of hazardous reactions

No data available.

### 10.4 Conditions to avoid

No data available.

### 10.5 Incompatible materials

Strong acids/alkalis, strong oxidising/reducing agents.

### 10.6 Hazardous decomposition products

Under fire conditions, may decompose and emit toxic fumes.

Other decomposition products - no data available.

## 11. TOXICOLOGICAL INFORMATION

### 11.1 Information on toxicological effects

#### Acute toxicity

Classified based on available data. For more details, see section 2

#### Skin corrosion/irritation

Classified based on available data. For more details, see section 2

#### Serious eye damage/irritation

Classified based on available data. For more details, see section 2

#### Respiratory or skin sensitization

Classified based on available data. For more details, see section 2

---

#### **Germ cell mutagenicity**

Classified based on available data. For more details, see section 2

#### **Carcinogenicity**

IARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.

NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.

OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.

#### **Reproductive toxicity**

Classified based on available data. For more details, see section 2

#### **Specific target organ toxicity - single exposure**

Classified based on available data. For more details, see section 2

#### **Specific target organ toxicity - repeated exposure**

Classified based on available data. For more details, see section 2

#### **Aspiration hazard**

Classified based on available data. For more details, see section 2

#### **Additional information**

This information is based on our current knowledge. However the chemical, physical, and toxicological properties have not been completely investigated.

## **12. ECOLOGICAL INFORMATION**

### **12.1 Toxicity**

No data available.

### **12.2 Persistence and degradability**

No data available.

### **12.3 Bioaccumulative potential**

No data available.

### **12.4 Mobility in soil**

No data available.

### **12.5 Results of PBT and vPvB assessment**

PBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.

### **12.6 Other adverse effects**

No data available.

## **13. DISPOSAL CONSIDERATIONS**

### **13.1 Waste treatment methods**

#### **Product**

Dispose substance in accordance with prevailing country, federal, state and local regulations.



---

**Contaminated packaging**

Conduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.

**14. TRANSPORT INFORMATION****DOT (US)**

Proper shipping name: Not dangerous goods

UN number: -

Class: -

Packing group: -

**IMDG**

Proper shipping name: Not dangerous goods

UN number: -

Class: -

Packing group: -

**IATA**

Proper shipping name: Not dangerous goods

UN number: -

Class: -

Packing group: -

**15. REGULATORY INFORMATION****SARA 302 Components:**

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

**SARA 313 Components:**

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**SARA 311/312 Hazards:**

No SARA Hazards.

**Massachusetts Right To Know Components:**

No components are subject to the Massachusetts Right to Know Act.

**Pennsylvania Right To Know Components:**

No components are subject to the Pennsylvania Right to Know Act.

**New Jersey Right To Know Components:**

No components are subject to the New Jersey Right to Know Act.

**California Prop. 65 Components:**

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.

**16. OTHER INFORMATION**

---

Copyright 2023 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

## SAMPLE INFORMATION

CAS NO.: 500287-72-9

Sample information:

Vial: 2:D,3

Injection #: 1

Injection Volume: 0.30 ul

Run Time: 2.8 Minutes

Sample Set Name: 20230220

Acquired By: LY

Date Acquired: 2/20/2023 3:00:25 PM CST

Acq. Method Set: 1\_POS\_2MIN


Date Processed: 2/20/2023 3:14:38 PM CST,

Processing Method: PDA\_01, MS\_scan

Channel Name: PDA Ch1 214nm@4.8nm, MS TIC,


Column Name: A-RP-985

### Auto-Scaled Chromatogram




Processed Channel Descr. PDA Ch2 254nm@4.8nm

### Auto-Scaled Chromatogram



Processed Channel Descr. PDA Ch1 214nm@4.8nm

### Auto-Scaled Chromatogram



Processed Channel Descr. ACQ-SQD2 1: MS Scan MS TIC, Smoothed by 9 point Savitzky-Golay Filter., Time offset by -0.053 mins. (1: 150.00-1000.00 ES+, Centroid, CV=30)

Peak Results  
Channel Name: PDA Ch2 254nm@4.8nm

	RT	Width (sec)	Area	Height	% Area	Base Peak (Combined) (m/z)	Channel Name
1	0.607	2.850	899	601	0.17	151.06	PDA Ch2 254nm@4.8nm
2	0.799	5.050	533601	590513	99.83	151.96	PDA Ch2 254nm@4.8nm


Peak Results  
Channel Name: PDA Ch1 214nm@4.8nm

	RT	Width (sec)	Area	Height	% Area	Base Peak (Combined) (m/z)	Channel Name
1	0.626	2.700	1547	1679	0.17	151.12	PDA Ch1 214nm@4.8nm
2	0.799	5.650	905932	1000599	99.71	151.98	PDA Ch1 214nm@4.8nm
3	1.267	2.500	1059	1173	0.12	151.98	PDA Ch1 214nm@4.8nm

Peak Results  
Channel Name: MS TIC

	RT	Width (sec)	Area	Height	% Area	Base Peak (Combined) (m/z)	Channel Name
1	0.801	6.963	449593240	162832935	100.00	367.07	MS TIC

Match Plot



Retention Time 0.801 Channel Name MS TIC

# Safety Data Sheet

Revision Date: Jan.-29-2022  
Print Date: Aug.-19-2022

## 1. PRODUCT AND COMPANY IDENTIFICATION

### 1.1 Product identifier

Product name : Rilpivirine  
Catalog No. : CS-0440  
CAS No. : 500287-72-9

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, manufacture of substances.

### 1.3 Details of the supplier of the safety data sheet

Company: ChemScene LLC  
Tel: 610-426-3128  
Fax: 888-484-5008  
E-mail: sales@chemscene.com

### 1.4 Emergency telephone number

Emergency Phone #: 610-426-3128

## 2. HAZARDS IDENTIFICATION

### 2.1 Classification of the substance or mixture

**GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)**

Acute toxicity, oral (Category 4), H302

### 2.2 GHS Label elements, including precautionary statements

Pictogram



Signal word Warning

Hazard statement(s)

H302 Harmful if swallowed

Precautionary statement(s)

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

### 2.3 Other hazards

None.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

Synonyms: R278474; TMC278; DB08864

Formula:	C <sub>22</sub> H <sub>18</sub> N <sub>6</sub>
Molecular Weight:	366.42
CAS No. :	500287-72-9

## 4. FIRST AID MEASURES

### 4.1 Description of first aid measures

#### Eye contact

Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.

#### Skin contact

Rinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.

#### Inhalation

Immediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.

#### Ingestion

Wash out mouth with water; Do NOT induce vomiting; call a physician.

### 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2).

### 4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

## 5. FIRE FIGHTING MEASURES

### 5.1 Extinguishing media

#### Suitable extinguishing media

Use water spray, dry chemical, foam, and carbon dioxide fire extinguisher.

### 5.2 Special hazards arising from the substance or mixture

During combustion, may emit irritant fumes.

### 5.3 Advice for firefighters

Wear self-contained breathing apparatus and protective clothing.

## 6. ACCIDENTAL RELEASE MEASURES

### 6.1 Personal precautions, protective equipment and emergency procedures

Use full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.

Refer to protective measures listed in sections 8.

### 6.2 Environmental precautions

Try to prevent further leakage or spillage. Keep the product away from drains or water courses.

### 6.3 Methods and materials for containment and cleaning up

Absorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.

## 7. HANDLING AND STORAGE

### 7.1 Precautions for safe handling

Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.

## 7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.

Recommended storage temperature: Storage temp. 2-8°C

Shipping at room temperature if less than 2 weeks.

## 7.3 Specific end use(s)

No data available.

# 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## 8.1 Control parameters

### Components with workplace control parameters

This product contains no substances with occupational exposure limit values.

## 8.2 Exposure controls

### Engineering controls

Ensure adequate ventilation. Provide accessible safety shower and eye wash station.

### Personal protective equipment

Eye protection	Safety goggles with side-shields.
Hand protection	Protective gloves.
Skin and body protection	Impervious clothing.
Respiratory protection	Suitable respirator.
Environmental exposure controls	Keep the product away from drains, water courses or the soil. Clean spillages in a safe way as soon as possible.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

## 9.1 Information on basic physical and chemical properties

Appearance	Solid
Odor	No data available
Odor threshold	No data available
pH	No data available
Melting/freezing point	245°C
Boiling point/range	634.1°C at 760 mmHg
Flash point	337.3°C
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Upper/lower flammability or explosive limits	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water Solubility	No data available
Partition coefficient	No data available
Auto-ignition temperature	No data available
Decomposition temperature	No data available
Viscosity	No data available
Explosive properties	No data available
Oxidizing properties	No data available

## 9.2 Other safety information

No data available.

## 10. STABILITY AND REACTIVITY

### 10.1 Reactivity

No data available.

### 10.2 Chemical stability

Stable under recommended storage conditions.

### 10.3 Possibility of hazardous reactions

No data available.

### 10.4 Conditions to avoid

No data available.

### 10.5 Incompatible materials

Strong acids/alkalis, strong oxidising/reducing agents.

### 10.6 Hazardous decomposition products

Under fire conditions, may decompose and emit toxic fumes.

Other decomposition products - no data available.

## 11. TOXICOLOGICAL INFORMATION

### 11.1 Information on toxicological effects

#### Acute toxicity

Classified based on available data. For more details, see section 2

#### Skin corrosion/irritation

Classified based on available data. For more details, see section 2

#### Serious eye damage/irritation

Classified based on available data. For more details, see section 2

#### Respiratory or skin sensitization

Classified based on available data. For more details, see section 2

#### Germ cell mutagenicity

Classified based on available data. For more details, see section 2

#### Carcinogenicity

IARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.

NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.

OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.

#### Reproductive toxicity

Classified based on available data. For more details, see section 2

#### Specific target organ toxicity - single exposure

Classified based on available data. For more details, see section 2

#### Specific target organ toxicity - repeated exposure

Classified based on available data. For more details, see section 2



**Aspiration hazard**

Classified based on available data. For more details, see section 2

**Additional information**

This information is based on our current knowledge. However the chemical, physical, and toxicological properties have not been completely investigated.

## 12. ECOLOGICAL INFORMATION

**12.1 Toxicity**

No data available.

**12.2 Persistence and degradability**

No data available.

**12.3 Bioaccumulative potential**

No data available.

**12.4 Mobility in soil**

No data available.

**12.5 Results of PBT and vPvB assessment**

PBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.

**12.6 Other adverse effects**

No data available.

## 13. DISPOSAL CONSIDERATIONS

**13.1 Waste treatment methods****Product**

Dispose substance in accordance with prevailing country, federal, state and local regulations.

**Contaminated packaging**

Conduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.

## 14. TRANSPORT INFORMATION

**DOT (US)**

Proper shipping name: Not dangerous goods

UN number: -

Class: -

Packing group: -

**IMDG**

Proper shipping name: Not dangerous goods

UN number: -

Class: -

Packing group: -

**IATA**

Proper shipping name: Not dangerous goods

UN number: -

Class: -

Packing group: -

## 15. REGULATORY INFORMATION

### **SARA 302 Components:**

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

### **SARA 313 Components:**

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### **SARA 311/312 Hazards:**

No SARA Hazards.

### **Massachusetts Right To Know Components:**

No components are subject to the Massachusetts Right to Know Act.

### **Pennsylvania Right To Know Components:**

No components are subject to the Pennsylvania Right to Know Act.

### **New Jersey Right To Know Components:**

No components are subject to the New Jersey Right to Know Act.

### **California Prop. 65 Components:**

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.

## 16. OTHER INFORMATION

Copyright 2022 ChemScene. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. ChemScene disclaims all liability for any damage resulting from handling or from contact with this product.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA